about
In-Cell Activation of Organo-Osmium(II) Anticancer Complexes.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.The potent oxidant anticancer activity of organoiridium catalysts.The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway.Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design.Systems approach to metal-based pharmacology.Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells.Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.Enhancement of Selectivity of an Organometallic Anticancer Agent by Redox Modulation.Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.The potent anti-cancer activity of Dioclea lasiocarpa lectin.Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosis.The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts.A novel dual-functioning ruthenium(II)-arene complex of an anti-microbial ciprofloxacin derivative - Anti-proliferative and anti-microbial activity.Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes.Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD(+) and pyruvate, and antiproliferative activity.Precious metal carborane polymer nanoparticles: characterisation of micellar formulations and anticancer activity.Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells.Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites for Organo-Osmium Complex in Human Ovarian Cancer Cells.Next-generation metal anticancer complexes: multitargeting via redox modulation.Contrasting cellular uptake pathways for chlorido and iodido iminopyridine ruthenium arene anticancer complexes.Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.Unexpected crosslinking and diglycation as advanced glycation end-products from glyoxal.Cyclic Peptide-Polymer Nanotubes as Efficient and Highly Potent Drug Delivery Systems for Organometallic Anticancer Complexes.Supramolecular Photoactivatable Anticancer Hydrogels.Spin-labelled photo-cytotoxic diazido platinum(iv) anticancer complex.Asymmetric transfer hydrogenation by synthetic catalysts in cancer cells.Half-Sandwich Arene Ruthenium(II) and Osmium(II) Thiosemicarbazone Complexes: Solution Behavior and Antiproliferative Activity.Effect of sulfonamidoethylenediamine substituents in RuII arene anticancer catalysts on transfer hydrogenation of coenzyme NAD+ by formate.Organometallic conjugates of the drug sulfadoxine for combatting antimicrobial resistance.Microfocus x-ray fluorescence mapping of tumour penetration by an organo‑osmium anticancer complex.New activation mechanism for half-sandwich organometallic anticancer complexes.Transfer Hydrogenation and Antiproliferative Activity of Tethered Half-Sandwich Organoruthenium Catalysts.Correction to Organometallic Iridium(III) AnticancerComplexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis.Mitochondria-targeted spin-labelled luminescent iridium anticancer complexes.In Vivo Selectivity and Localization of Reactive Oxygen Species (ROS) Induction by Osmium Anticancer Complexes That Circumvent Platinum ResistanceNanoparticles of chitosan conjugated to organo-ruthenium complexesPhotoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer ProdrugsSynthesis and Mode of Action Studies on Iridium(I)-NHC Anticancer Drug Candidates
P50
Q33626165-6ECC3C2E-755B-44E9-8055-17642634D3AAQ34331245-0829CBBF-9E70-49DA-A036-CF5F47CE4F8AQ34488624-17B84A47-B1F9-4B8B-B65B-6A7914043051Q34569546-5286F4A4-6E38-4B9F-BBDE-A41C514A107FQ35247064-CC73CC1D-105F-4BBF-9BF0-43A05A80A616Q35378343-EB5253AB-FDF0-4C41-97BE-4710CC88846DQ35863615-8A1068B5-1374-44A8-A4A5-4A17E5C5EB0CQ35895492-BF953A41-4E5C-4450-B9A9-4F5876F0CB0AQ36146681-B97AEBEA-841C-404A-9079-59DE6D674C2CQ36952837-C4EBA150-DACE-47AF-8181-D83926B4F63DQ38653523-1E54E056-DA39-4163-B869-36DA4BCA212AQ38772710-1C71167D-422C-432E-8F32-BFCE2295290EQ38775808-1547FB84-C462-4154-A23F-8F0CAF6A174CQ38784981-DF804930-EC33-4A37-8237-69E84774D9FCQ38795232-B766D6F7-A56A-4536-8375-5625BD414315Q38817152-C9FD747F-78D6-44D8-AF12-30FD893FBEE9Q38951818-8FB35E13-573F-4FAC-A49F-495D8B271545Q39011794-E7FFE710-C0C2-4DED-A496-195AFEFC5D28Q39067087-E7A369BC-86E1-493B-B11A-7E0F03DA0E9BQ39121404-B78D1714-50F3-4790-BF1C-313416195775Q39247606-D69DE27E-0EA9-4C1F-9102-EBD745118C96Q42400560-EF8B1FD6-554C-4A63-8240-B33891B4DFBAQ46262834-AF07002E-E0D0-4387-8BF8-A61BF37742BCQ46825370-BE967C7A-6611-4FF4-B25E-71A7D03030A8Q48270651-BDC4BC16-F697-4F3D-B348-98FBBFC80B6EQ48271205-7593B712-A16C-4840-9D97-06A3B4E33023Q50201867-9BEB8AED-C962-48B6-9501-CA63D9BBAEB0Q51749836-4F994FA2-0401-45E0-B41D-EABC57451A34Q52313236-C9771646-1BC9-4381-9BFA-6772763D3C08Q52322842-B9C58C63-16CB-45BE-B23F-EFDCF37B86B6Q52589813-39B4A04D-A213-4DE5-86FE-E74468C7FC8CQ53687400-9A647608-7ED5-4E36-BA05-C3283434324AQ54974394-85D73C4E-3C5F-484B-88AC-6EE67E029F6DQ54978767-AE4BC3AF-B098-4C83-9FA2-45FBC83EFBD4Q55210125-FF6E1540-7D39-48FE-BC54-8215C4F10A08Q55397032-0181B036-8EE9-4EBA-8E73-B323C59D587BQ56982978-453F9D78-D420-4A64-AF6F-1A5DA869FD1AQ57393553-414EAEA9-C32A-4AC8-B4A0-C60F4F9E282EQ58543166-50A4854F-0EA6-43CD-BEC6-A5FA51D86960Q58858872-47685572-2CE5-4E16-9AE0-100BEBA9E828
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Isolda Romero-Canelón
@ast
Isolda Romero-Canelón
@en
Isolda Romero-Canelón
@es
Isolda Romero-Canelón
@nl
Isolda Romero-Canelón
@sl
type
label
Isolda Romero-Canelón
@ast
Isolda Romero-Canelón
@en
Isolda Romero-Canelón
@es
Isolda Romero-Canelón
@nl
Isolda Romero-Canelón
@sl
prefLabel
Isolda Romero-Canelón
@ast
Isolda Romero-Canelón
@en
Isolda Romero-Canelón
@es
Isolda Romero-Canelón
@nl
Isolda Romero-Canelón
@sl
P108
P1053
A-5852-2015
P106
P1153
55502708800
57201603635
P21
P31
P3829
P3835
isolda-romero-canelon
P496
0000-0003-3847-4626